New level of
effectiveness for fungal
MYC-053 is a new
frontier in antifungal
Passionately committed to the development of innovative antifungals to treat life-threatening multi-drug resistant infections
TGV-Therapeutics is a biopharmaceutical company focused on the development of novel drugs that can address unmet clinical needs in the treatment of life-threatening systemic fungal infections.
Our lead product candidate, MYC-053, is a novel, antifungal agent that is structurally distinct from the three main classes of antifungal antibiotics.
The effectiveness of MYC-053 against the currently incurable multidrug-resistant fungal infections is attributed to its distinct chemical structure.
We developed MYC-053 as an oral drug primarily for the treatment of harmful fungal diseases in humans.
TGV-Therapeutics is a biopharmaceutical company committed to and developing novel antifungal antibiotics that will bring therapy of invasive fungal infections to a principally new level of effectiveness.
TGV -Therapeutics’ ultimate goal is to apply the MYC-053 to some of the most deadly fungal infections — those caused by multiresistant Candida species, including Candida auris.